key: cord-0688603-rzef9pj4
authors: Jain, Amit; Lamperti, Massimo; Doyle, D. John; Lobo, Francisco A.
title: Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127: e32–4
date: 2021-09-20
journal: Br J Anaesth
DOI: 10.1016/j.bja.2021.09.008
sha: 1967d58abf682b17e58692b71c8bab9cfb194cec
doc_id: 688603
cord_uid: rzef9pj4

nan

EditordWe enjoyed the article by Hirota and Lambert 1 postulating therapeutic potential for various anaesthesia drugs in COVID-19. However, we believe that the authors' approach of categorising these drugs as pro-or antiviral against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) based on sigma-1 receptor (Sig-1R) agonistic or antagonistic properties, respectively, is a potential oversimplification.

Although recent publications support antiviral properties for ligands with moderate to high affinity for Sig-1R, it is undetermined which pharmacological activity of Sig-1R ligands is responsible for inhibiting SARS-CoV-2 replication. 2, 3 Considering the analogy that both к-opioid receptor agonists and antagonists inhibit cocaine-induced replication of human immunodeficiency virus, 4 it may be possible that any ligand (i.e. agonist, antagonist, or allosteric modulator) with high affinity for Sig-1R could offer antiviral activity by competing with the viral proteins, thus preventing the hijacking of Sig-1R by SARS-CoV-2 non-structural protein 6 (nsp6).

As part of innate immune defences, macro-autophagy targets viruses and viral components for lysosomal degradation preventing virus-induced necrosis or apoptosis of the infected cell (Fig. 1) , and exposes pathogen-associated molecular patterns to facilitate recognition. However, recent studies suggest that several strategies used by the SARS-CoV-2 virus exploit autophagy to promote viral replication while inhibiting degradation of viral proteins. 5 One key example is the interaction of SARS-CoV-2 nsp6 protein with Sig-1R. 3 Although the nature of the nsp6 interaction (i.e. agonistic or antagonistic or allosteric modulator) with Sig-1R remains unknown, this interaction induces the formation of double membrane vesicles and or autophagosomes carrying SARS-CoV-2 replication complex, but inhibits autolysosome formation. 2,3 Thus, SARS-CoV-2 induces defective autophagy and compromises the ability of autophagosomes to deliver viral components to lysosomes for subsequent degradation. 5, 6 Defective autophagy may also impair antigen presentation, inhibit innate and adaptive immune responses, and reduce recycling of antiviral immune mediators. 6 Sig-1R is a chaperone protein that is a key regulator of autophagosomeelysosome fusion, a common critical step in various forms of macro-autophagy and mitophagy, and degradation of defective mitochondria. 7 Although Sig-1R ablation reduces the fusion of autophagosomes and lysosomes and impairs autophagosome clearance without affecting upstream pathways, Sig-1R agonists promote effective autophagy. 7 8 In amyotrophic lateral sclerosis, Sig-1R mutants did not affect the formation of autophagosomes but produced aberrant accumulation of autophagic cargo, including defective mitochondria. 8 Mutant Sig-1R colocalises with accumulated autophagosomes, suggesting a role for Sig-1R in the fusion of autophagosomes and lysosomes. 8 Nonetheless, Sig-1R agonists improve autophagosome clearance by inducing autolysosome formation and provide clinical benefits in neurological and psychiatric disorders associated with impaired or defective autophagy. 9 As SARS-CoV-2 utilises the nsp6 protein to support its replication by hijacking the Sig-1R to prevent autophagosomeelysosome fusion while activating omegasome formation, 6 it is possible that the nsp6 protein acts by mediating Sig-1R antagonism. We believe that high-affinity Sig-1R agonist ligands cannot only compete with nsp6 proteins for Sig-1R, but unlike Sig-1R antagonist ligands, these drugs also promote viral clearance and improve cell survival by supporting autophagic flux. 3 Notably, Sig-1R agonists are generally anti-inflammatory, reduce oxidative and endoplasmic reticulum stress, improve mitochondrial biogenesis, and reduce cytokine response, whereas Sig-1R antagonists oppositely affect these processes. 3, 9 Although it is possible that both Sig-1R agonists and Sig-1R antagonists possess antiviral effects, 3 Diagram of the mechanisms of SARS-CoV-2 Nsp6 protein and Sig-1R interaction inducing defective autophagy, along with proposed mechanisms for Sig-1R agonists over Sig-1R antagonists for treating SARS-CoV-2 infections. Macro-autophagy is the main pathway, eradicating damaged organelles and viral particles. An early autophagy step is the formation of endoplasmic reticulum (ER) structures called omegasomes (highlighted as a dashed black box); these are the sites from which sack-like phagophores expand to accommodate substances destined for degradation by lysosomal-mediated macro-autophagy. SARS-CoV-2 Nsp6 proteins interact with Sig-1R to generate autophagosomes from the ER. The Nsp6eSig-1R interaction also limits autophagosome expansion, compromising the ability of autophagosomes to deliver viral components to lysosomes for degradation. Immature double-membrane autophagosomes act as SARS-CoV-2 replication organelles. Sig-1R agonists may prevent Nsp6 protein binding with Sig-1R and induce autolysosome formation, promoting autophagy while inhibiting virus-induced defective autophagy. Sig-1R agonists also inhibit cytokine responses and promote cell survival. Sig-1R antagonists may prevent Nsp6-Sig-1R inhibition of virus-induced defective autophagy. However, cellular autophagy processes necessary to clear damaged organelles and misfolded proteins are also hampered, resulting in direct cytotoxic effects. ER, endoplasmic reticulum; IL-6, interlukin-6; NF-кB, nuclear factor kappa light chain enhancer of activated B cells; nsp6, non-structural protein 6; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; Sig-1R, sigma-1 receptor. Red lines with blocked ends denote inhibition; green arrows denote activation. e2 -Correspondence benefits in COVID-19 disease outcomes are immunomodulatory or anti-inflammatory in nature (e.g. dexamethasone and tocilizumab), and that none of the clinically tested antiviral drugs has shown any mortality benefit (News e RECOVERY Trial), Sig-1R agonists may be a better option for treatment of COVID-19 3 (Fig. 1) . This approach is supported by a clinical trial showing reduced risk of progression to severe COVID-19 in adults treated with fluvoxamine, a high-affinity Sig-1R agonist. 10 In contrast, haloperidol, a potent Sig-1R antagonist, failed to provide clinical benefit in COVID-19 patients. 10 Furthermore, Sig-1R knockout models are associated with increased mortality in sepsis, whereas fluvoxamine improved survival in lipopolysaccharide-treated mice. 11 Fluoxetine, another potent Sig-1R agonist, has been shown to inhibit SARS-CoV-2 replication, albeit by alternate mechanisms. 11 Similarly, the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 nsp6 is attributable to the different binding properties of these drugs with the nsp6 protein 12 and is not secondary to their binding with Sig-1R. Hence, it may be possible that the antiviral effects of Sig-1R ligands are mediated by an alternate mechanism. 3 This makes it important to prefer anti-inflammatory Sig-1R agonists over pro-inflammatory Sig-1R antagonists in the treatment of COVID-19. 3 The argument is supported by the observation that Sig-1R antagonist NE-100 inhibited SARS-CoV-2 infection and replication in human cardiomyocytes, but also disrupted cytoskeletal architecture and contractility. 13 We thus believe that anaesthesia drugs with Sig-1R agonistic actions may be more beneficial against COVID-19 than those with Sig-1R antagonistic actions. As COVID-19 is a multisystem disorder with hyper-pro-inflammatory pathophysiology, 14 anaesthesia drugs such as dexmedetomidine that possess anti-inflammatory, cytoprotective, and organoprotective effects may be beneficial in COVID-19. 15 Apart from angiotensin converting enzyme 2 (ACE2) and Sig-1R, SARS-CoV-2 utilises other binding sites such as neuropilin-1 (NRP-1) 16 and sigma-2 receptor (Sig-2R) 17 for infecting host cells that may have limited association with anaesthesia drugs.

The SARS-CoV-2 spike protein CendR motif interacts with the b1b2 domain of NRP-1 to infect host cells including ACE2deficient and TMPRSS2-negative endothelial cells. 16 This interaction can induce antinociception via subversion of the vascular endothelial growth factor (VEGF)/NRP-1 activity, 16 theoretically altering the potency of analgesics. Notably, hyperoxia can downregulate NRP-1, whereas dexmedetomidine reverses hyperoxia-induced NRP-1 downregulation and improves neuronal plasticity. 18 Whether this reflects in an increased SARS-CoV-2 cellular entry or in reduced neurological manifestations of COVID-19 warrants investigation. In addition, к-opioid receptor agonists downregulate NRP-1 expression and inhibit VEGF signalling 19 ; it is not clear if this is beneficial in controlling SARS-CoV-2 infection or COVID-19associated angiogenesis. Finally, based on Auto-Dock Vina data, codeine and methyl-morphine have high binding affinities for ACE2 receptors, 20 although the antiviral role of opioids remains to be determined.

In a recent pre-print, Sig-2R was identified as a binding protein for SARS-CoV-2 viral protein Orf9c, and this interaction was found to increase Sig-2R/ACE2 complex formation and promote SARS-CoV-2 cell entry. 17 In the same study, Sig-2R ablation inhibited SARS-CoV-2 viral uptake, and decreased inflammatory and thrombotic effects in the modulation of the complement cascade.

In conclusion, at present it is unclear whether a Sig-1R agonist or Sig-1R antagonist would be better for inhibiting SARS-CoV-2 replication. Experiments comparing these ligands in the same assay are warranted. Until then, classifying antiinflammatory anaesthesia drugs such as dexmedetomidine 21 as 'pro-viral' based on their agonistic activity on Sig-1R is not supported by evidence.

ML is a member of the associate editorial board of the British Journal of Anaesthesia. The other authors have no conflicts to declare.

Anaesthesia-related drugs and SARS-CoV-2 infection

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry

Repurposing sigma-1 receptor ligands for COVID-19 therapy?

k-Opioid receptor ligands inhibit cocaineinduced HIV-1 expression in microglial cells

Manipulation of autophagy by SARS-CoV-2 proteins

Coronavirus NSP6 restricts autophagosome expansion

SIGMAR1/Sigma-1 receptor ablation impairs autophagosome clearance

The Sigma-1 receptor at the crossroad of proteostasis, neurodegeneration, and autophagy

Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

Fluoxetine can inhibit SARS-CoV-2 in vitro

Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis

Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility

Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: Correspondence -e3

molecular mechanisms and implications

Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU

SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia

Differential gene expression by RNA-Seq in Sigma-2 Receptor/TMEM97 knockout cells reveals its role in complement activation and SARS-CoV-2 viral uptake

Neuroprotective effects of dexmedetomidine against hyperoxia-induced injury in the developing rat brain

Opioid receptor ligands regulate angiogenesis in development and in tumours: k opioids act as anti-angiogenic factors

Angiotensin converting enzyme-2 as therapeutic target in COVID-19

Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units